• Publications
  • Influence
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous
TLDR
Matched related allogeneic transplantations for ALL in first complete remission provide the most potent antileukemic therapy and considerable survival benefit for standard-risk patients, but the transplantation-related mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse risk. Expand
Hypersensitivity reactions from taxol.
TLDR
Hypersensitivity reactions to taxol have been one of the toxicities observed with administration of this drug and guidelines are provided to prevent or minimize such toxicity and treat reactions if they still occur. Expand
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern
TLDR
The observation that Ho-Tr and, for the first time, karyotype complexity confer an increased risk of treatment failure demonstrates that cytogenetic subgroups other than the Ph chromosome can and should be used to risk stratify adults with ALL in future trials. Expand
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
TLDR
A postinduction course of high-dose cytarabine can provide equivalent disease-free survival and somewhat better overall survival than autologous marrow transplantation in adults with acute myeloid leukemia. Expand
PHF6 mutations in T-cell acute lymphoblastic leukemia
TLDR
PHF6 is identified as a new X-linked tumor suppressor in T-ALL and a strong genetic interaction between PHF6 loss and aberrant expression of TLX transcription factors in the pathogenesis of this disease is pointed to. Expand
All-trans-retinoic acid in acute promyelocytic leukemia.
TLDR
All-trans-retinoic acid as induction or maintenance treatment improves disease-free and overall survival as compared with chemotherapy alone and should be included in the treatment of acute promyelocytic leukemia. Expand
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
TLDR
Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects, in a phase II, single-arm, multicenter trial. Expand
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
TLDR
The data demonstrate that achieving CR with induction therapy is indispensable for long-term survival in adult patients with ALL, and the induction regimen was highly efficacious as remission-inducing therapy. Expand
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
TLDR
Long-term follow-up of the North American Intergroup APL trial reported a benefit for all-trans retinoic acid (ATRA) in both induction and maintenance therapy in patients with acute promyelocytic leukemia (APL), and female sex, classical M3 morphology, and treatment-white blood cell count (WBC) interaction were each significantly associated with improved DFS. Expand
Outcome of transplantation for myelofibrosis.
TLDR
In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. Expand
...
1
2
3
4
5
...